July 25, 2016 06:35 PM EDT
R&D
Pharma

What's Gilead­'s next deal go­ing to look like? CEO Mil­li­gan cites block­buster fil­go­tinib pact

John Carroll

Editor & Founder

Gilead to­day man­aged to sur­prise the an­a­lysts who fol­low the com­pa­ny by guid­ing down on its shrink­ing rev­enue for its megablock­buster hep C fran­chise …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times